Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan

Apr 24 2018

• By Scrip Team

Charts — • Source: Shutterstock

Related Content

Sanofi's Generics Business To Be Sold To Private Equity Firm, Advent

Apr 17 2018

At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise

Apr 17 2018

In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts

Apr 18 2018

Dupixent Stopped at UK Gate For AD As EMA Agrees To Review It In Asthma

Apr 04 2018

Allergan Confident Data Support Bipolar Depression Addition To Vraylar's Label

Apr 05 2018

Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray

Apr 06 2018

Shire Rejects Multiple Equity-Loaded Takeda Offers, Allergan Declines To Bid

Apr 19 2018

End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity

Apr 05 2018

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

Apr 24 2018

Servier Acquires Shire Oncology Business For $2.4bn

Apr 16 2018

Servier's Shire Oncology Buy Gives Base For US Expansion

Apr 17 2018

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Allergan, Shire Battle In Dry Eye As Generics Advance

Jan 15 2018

Tumor Mutation Burden Biomarker Inches Closer To Acceptance In Cancer

Apr 20 2018

Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review

Apr 15 2018

Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)

Mar 04 2018

Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio

Feb 14 2018

Will Sanofi’s Dengvaxia Woes Spiral Beyond The Philippines?

Feb 06 2018

Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang

Feb 06 2018

AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids

Feb 21 2018

Bristol Debuts Opdivo/Yervoy Data In New First-Line Lung Cancer Bid

Feb 06 2018

Bristol/Pfizer's Eliquis Better For Preventing Strokes And Bleeding In Large Real-World Trial

Mar 12 2018

Biohaven Posts Positive Migraine Results, But Investors Are Wary

Mar 27 2018

Availability More Than Strategy Driving Takeda's Shire Interest?

Mar 29 2018

Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

Mar 22 2018

Shire May Split Up – But Punting On Bigger Decisions For Now

Jan 08 2018

Mylan Set To Develop Biosimilar Botox In Deal With Revance

Mar 01 2018

Ablynx, Bioverativ Buys Drive Sanofi's Hematology Reign

Jan 29 2018

Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow

Jan 19 2018

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

Nov 14 2017

Six Ways For PD-1 Lung Cancer Programs To Differentiate

May 11 2015

Related Companies

Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Les Laboratoires Servier

Pfizer Inc.

Amgen, Inc.

Allergan plc

Bristol Myers Squibb Company

Johnson & Johnson

Sanofi

Ablynx N.V.

Biogen, Inc.

Sanofi

Roche Holding AG

BioMarin Pharmaceutical Inc.

Regeneron Pharmaceuticals, Inc.

Zentiva Group a.s.

AbbVie Inc.

Eli Lilly and Company

Gilead Sciences, Inc.

Additional Topics

Sales & Earnings Companies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window